Compounds as mPGES-1 inhibitors

A method for treating a disease or condition mediated by or associated with enhanced mPGES-1 expression or activity, wherein the method comprises the step of administering to a subject suffering from the disease or condition an effective amount of a compound represented by general structure (I):

• wherein,
• T is a water-soluble vitamin E derivative having a core chromanyl or chromanyl quinone framework and a carboxylic acid moiety substituted at the 2-position, wherein T is connected to nitrogen via the carboxylic acid moiety, as such forming an amide moiety;
• L is a linker between the amide nitrogen atom and the distal nitrogen atom comprising 1 to 10 optionally substituted backbone atoms selected from carbon, nitrogen and oxygen;
• N* is represented by structure (IIa) or (IIb)
• R1 and R2 are each independently selected from hydrogen (H), C1-C6 alkyl or C1-C6 alkenyl, or R1 and R2 are joined together and thus form a second linker between the amide nitrogen atom and the distal nitrogen atom, or R1 is joined with a backbone atom of the linker L in a cyclic structure and/or R2 is joined with a backbone atom of the linker L in a cyclic structure;
• R3 is selected from hydrogen (H), C1-C6 alkyl or C1-C6 alkenyl, wherein the alkyl or alkenyl moiety may be substituted with one or more halogen atoms, hydroxyl moieties or (halo)alkoxy moieties, or R3 is absent when the distal nitrogen atom is part of an imine moiety;
• or optionally R3 is joined with a backbone atom of the linker L in a cyclic structure;
• and
• R4 is selected from hydrogen (H) or C1-C6 alkyl, wherein the alkyl moiety may be substituted with one or more halogen atoms or (halo)alkoxy moieties;
• X is an anion.